Answers are grounded in this paper and cite their sources.
Cross-sectional study reveals serum C3 serves as a biomarker for disease in middle-aged and elderly adults, indicating potential diagnostic utility.
Serum C3 is a promising diagnostic biomarker for MASLD in middle-aged and elderly adults, showing a distinct nonlinear relationship and strong discriminative ability. However, complement levels were not independently associated with liver fibrosis in this population. These findings suggest a potential role for C3 in MASLD diagnosis, but the cross-sectional design precludes causal inference, and further longitudinal studies are needed to confirm its clinical utility and elucidate underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: